D. Boral Capital Reaffirms “Buy” Rating for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $10.00 price target on the medical research company’s stock.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, January 9th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Cytosorbents presently has a consensus rating of “Hold” and an average price target of $5.38.

Cytosorbents Price Performance

CTSO stock opened at $0.59 on Thursday. The firm has a 50 day moving average of $0.69 and a 200-day moving average of $0.75. The company has a market cap of $37.24 million, a price-to-earnings ratio of -4.56 and a beta of 1.36. The company has a current ratio of 2.11, a quick ratio of 1.71 and a debt-to-equity ratio of 1.61. Cytosorbents has a 12-month low of $0.50 and a 12-month high of $1.39.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Wednesday, March 25th. The medical research company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.04). Cytosorbents had a negative return on equity of 131.86% and a negative net margin of 22.12%.The firm had revenue of $9.23 million during the quarter, compared to analyst estimates of $9.22 million. As a group, equities analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

Institutional investors have recently modified their holdings of the company. Avenir Corp lifted its stake in shares of Cytosorbents by 2.9% during the fourth quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock valued at $3,343,000 after buying an additional 147,261 shares during the period. Vanguard Group Inc. grew its stake in Cytosorbents by 3.7% in the 3rd quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock worth $2,059,000 after acquiring an additional 79,535 shares during the period. CIBC Bancorp USA Inc. purchased a new stake in Cytosorbents in the 3rd quarter worth approximately $161,000. Goldman Sachs Group Inc. raised its holdings in Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after acquiring an additional 37,519 shares during the last quarter. Finally, Citadel Advisors LLC raised its holdings in Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 36,790 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.